Fig. 2: Identification of VP-MCC selective targets. | Nature Communications

Fig. 2: Identification of VP-MCC selective targets.

From: High-throughput screening identifies Aurora kinase B as a critical therapeutic target for Merkel cell carcinoma

Fig. 2

A Drug target subcategories ranked by difference in mean AUC in VP-MCC and VN-MCC cell lines. Dark-purple bars indicate VP-MCC selectivity (AUC difference > 40, p < 0.1, AUC < 450 in all VP-MCC cell lines screened). P-values: BCL-XL: (p = 0.0007; n = 6), photosensitizer: (p = 0.037; n = 4), FLT: (p = 0.019; n = 4), VDR: (p = 0.094; n = 3), Topoisomerase II: (p = 0.069; n = 21), AURK: (p = 0.059; n = 18), MCL-1: (p = 0.043; n = 4), HDAC: (p = 0.034; n = 25), MMP: (p = 0.0024; n = 11). B Bubble plot demonstrating mean VN-MCC AUC vs. mean VP-MCC AUC for each compound class (size of bubble indicates number of agents in compound class). Purple bubbles highlight compound classes that selectively reduced VP-MCC viability (AUC difference > 30, p < 0.1, AUC < 450 in all VP-MCC cell lines screened). P-values: aurora kinase inhibitors: (p = 0.059; n = 21), regulators of histone epigenetic machinery: (p = 0.043; n = 44), regulators of apoptosis: (p = 0.013; n = 39). A two-sided t-test was used to calculate the p-values. n = number of compounds.

Back to article page